Klotho Neurosciences (KLTO) Competitors $0.78 -0.02 (-1.90%) As of 08/14/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock KLTO vs. CYBN, TIL, LYEL, CRDF, LFVN, DERM, ACRS, RAPT, SLS, and PBYIShould you be buying Klotho Neurosciences stock or one of its competitors? The main competitors of Klotho Neurosciences include Cybin (CYBN), Instil Bio (TIL), Lyell Immunopharma (LYEL), Cardiff Oncology (CRDF), Lifevantage (LFVN), Journey Medical (DERM), Aclaris Therapeutics (ACRS), Rapt Therapeutics (RAPT), SELLAS Life Sciences Group (SLS), and Puma Biotechnology (PBYI). These companies are all part of the "pharmaceutical products" industry. Klotho Neurosciences vs. Its Competitors Cybin Instil Bio Lyell Immunopharma Cardiff Oncology Lifevantage Journey Medical Aclaris Therapeutics Rapt Therapeutics SELLAS Life Sciences Group Puma Biotechnology Klotho Neurosciences (NASDAQ:KLTO) and Cybin (NYSE:CYBN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk. Do insiders and institutionals believe in KLTO or CYBN? 20.1% of Klotho Neurosciences shares are held by institutional investors. Comparatively, 17.9% of Cybin shares are held by institutional investors. 26.7% of Klotho Neurosciences shares are held by insiders. Comparatively, 15.0% of Cybin shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is KLTO or CYBN more profitable? Cybin's return on equity of -37.58% beat Klotho Neurosciences' return on equity.Company Net Margins Return on Equity Return on Assets Klotho NeurosciencesN/A -1,779.01% -275.01% Cybin N/A -37.58%-36.59% Which has better earnings and valuation, KLTO or CYBN? Klotho Neurosciences is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKlotho NeurosciencesN/AN/A-$6.15M-$0.36-2.16CybinN/AN/A-$57.88M-$3.88-1.85 Do analysts recommend KLTO or CYBN? Cybin has a consensus price target of $85.00, indicating a potential upside of 1,085.50%. Given Cybin's stronger consensus rating and higher possible upside, analysts plainly believe Cybin is more favorable than Klotho Neurosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Klotho Neurosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Cybin 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Which has more risk and volatility, KLTO or CYBN? Klotho Neurosciences has a beta of 10.9, indicating that its share price is 990% more volatile than the S&P 500. Comparatively, Cybin has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500. Does the media favor KLTO or CYBN? In the previous week, Klotho Neurosciences had 4 more articles in the media than Cybin. MarketBeat recorded 7 mentions for Klotho Neurosciences and 3 mentions for Cybin. Klotho Neurosciences' average media sentiment score of 0.27 beat Cybin's score of 0.24 indicating that Klotho Neurosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Klotho Neurosciences 0 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cybin 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryKlotho Neurosciences and Cybin tied by winning 7 of the 14 factors compared between the two stocks. Get Klotho Neurosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for KLTO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KLTO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KLTO vs. The Competition Export to ExcelMetricKlotho NeurosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$36.57M$2.48B$5.61B$9.84BDividend YieldN/A1.76%4.61%4.07%P/E Ratio-2.1622.0530.2925.74Price / SalesN/A742.42463.41115.83Price / CashN/A184.4138.2159.48Price / Book19.484.838.826.15Net Income-$6.15M$31.61M$3.25B$265.06M7 Day Performance-13.85%4.55%3.70%2.60%1 Month Performance-42.30%5.69%5.84%2.83%1 Year PerformanceN/A12.71%29.92%25.58% Klotho Neurosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KLTOKlotho NeurosciencesN/A$0.78-1.9%N/AN/A$36.57MN/A-2.16N/AUpcoming EarningsCYBNCybin2.6131 of 5 stars$7.57-1.4%$85.00+1,022.9%N/A$178.58MN/A-1.7350News CoverageTILInstil Bio3.0994 of 5 stars$26.99+9.1%$119.00+340.9%+170.1%$177.05MN/A-2.25410News CoverageEarnings ReportLYELLyell Immunopharma3.3013 of 5 stars$11.43+0.5%$15.00+31.2%-55.2%$176.71M$60K-0.46270Trending NewsEarnings ReportGap DownCRDFCardiff Oncology2.0472 of 5 stars$2.57+2.4%$11.70+355.3%+11.9%$170.98M$680K-2.9520LFVNLifevantage4.2195 of 5 stars$13.44+1.1%$30.50+126.9%+71.0%$169.21M$200.16M19.48260DERMJourney Medical1.881 of 5 stars$7.21+1.0%$9.50+31.8%+52.5%$167.99M$56.13M-18.4990News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionACRSAclaris Therapeutics2.6379 of 5 stars$1.55-0.6%$8.71+462.2%+44.4%$167.83M$18.72M-1.12100RAPTRapt Therapeutics4.5879 of 5 stars$10.10-6.1%$20.57+103.7%-34.3%$167.05M$1.53M-0.5380Analyst ForecastSLSSELLAS Life Sciences Group2.8757 of 5 stars$1.62+1.9%$7.00+332.1%+29.2%$161.64M$1M-4.2610News CoverageEarnings ReportPBYIPuma Biotechnology4.1339 of 5 stars$3.22+1.3%$7.00+117.4%+95.9%$159.81M$230.50M4.18200Gap Down Related Companies and Tools Related Companies Cybin Competitors Instil Bio Competitors Lyell Immunopharma Competitors Cardiff Oncology Competitors Lifevantage Competitors Journey Medical Competitors Aclaris Therapeutics Competitors Rapt Therapeutics Competitors SELLAS Life Sciences Group Competitors Puma Biotechnology Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KLTO) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Klotho Neurosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Klotho Neurosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.